Chlamydia pneumoniae -Mediated Inflammation in Atherosclerosis: A Meta-Analysis

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Filardo, Simone ^a   Di Pietro, Marisa ^a   Farcomeni, Alessio ^a   Schiavoni, Giovanna ^a   Sessa, Rosa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; C REACTIVE PROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHLAMYDIA PNEUMONIAE; CHLAMYDIAL PNEUMONIA; CORONARY ARTERY ATHEROSCLEROSIS; CROSS-SECTIONAL STUDY; HUMAN; INFLAMMATION; META ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLISHING; REVIEW; SEROPREVALENCE; ANIMAL; CHLAMYDOPHILA INFECTION; COMPLICATION; IMMUNOLOGY; METABOLISM;

CHLAMYDOPHILA PNEUMONIAE;

ANIMALS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FIBRINOGEN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6;

EID: 84940421432     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/378658     Document Type: Review

References (69)

1. M. Rafieian-Kopaei, M. Setorki, M. Doudi, A. Baradaran, and H. Nasri, "Atherosclerosis: process, indicators, risk factors and new hopes," International Journal of PreventiveMedicine, vol. 5, no. 8, pp. 927-946, 2014.
2. H. Mangge, K. Becker, D. Fuchs et al. , "Antioxidants, inflammation and cardiovascular disease," World Journal of Cardiology, vol. 6, no. 6, pp. 462-477, 2014.
3. L. Stoner, A. A. Lucero, B. R. Palmer, L. M. Jones, J. M. Young, and J. Faulkner, "Inflammatory biomarkers for predicting cardiovascular disease," Clinical Biochemistry, vol. 46, no. 15, pp. 1353-1371, 2013.
4. S. Pant, A. Deshmukh, G. S. Gurumurthy et al. , "Inflammation and atherosclerosis-revisited," Journal of Cardiovascular Pharmacology and Therapeutics, vol. 19, no. 2, pp. 170-178, 2014.
5. World Health Organization, Global Status Report on Noncommunicable Diseases 2010, World Health Organization, Geneva, Switzerland, 2011.
6. M. E. RosenfeldandL. A. Campbell, "Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis," Thrombosis and Haemostasis, vol. 106, no. 5, pp. 858-867, 2011.
7. R. Sessa, M. Di Pietro, S. Filardo, and O. Turriziani, "Infectious burden and atherosclerosis: a clinical issue," World Journal of Clinical Cases, vol. 2, no. 7, pp. 240-249, 2014.
8. P. Saikku, M. Leinonen, K. Mattila et al. , "Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction," The Lancet, vol. 332, no. 8618, pp. 983-986, 1988.
9. J. Boman and M. R. Hammerschlag, "Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies," Clinical Microbiology Reviews, vol. 15, no. 1, pp. 1-20, 2002.
10. H. C. Jha, P. Srivastava, R. Sarkar, J. Prasad, and A. Mittal, "Chlamydia pneumoniae IgA and elevated level of IL-6 may synergize to accelerate coronary artery disease," Journal of Cardiology, vol. 52, no. 2, pp. 140-145, 2008.
11. R. Joshi, B. Khandelwal,D. Joshi, and O. P. Gua, "Chlamydophila pneumoniae infection and cardiovascular disease," North American Journal of Medical Sciences, vol. 5, no. 3, pp. 169-181, 2013.
12. N. Sakurai-Komada, H. Iso, K. A. Koike et al. , "Association between Chlamydophila pneumoniae infection and risk of coronary heart disease for Japanese: the JPHCstudy," Atherosclerosis, vol. 233, no. 2, pp. 338-342, 2014.
13. A. Shor and J. I. Phillips, "Histological and ultrastructural findings suggesting an initiating role for Chlamydia pneumoniae in the pathogenesis of atherosclerosis: a study of 50 cases," Cardiovascular Journal of Southern Africa, vol. 11, no. 1, pp. 16-23, 2000.
14. D. Virok, Z. Kis, L. Kari et al. , "Chlamydophila pneumoniae and human cytomegalovirus in atherosclerotic carotid plaques-combined presence and possible interactions," Acta Microbiologica et ImmunologicaHungarica, vol. 53,no. 1, pp. 35-50, 2006.
15. H. C. Jha, P. Srivastava, A. Divya, J. Prasad, and A. Mittal, "Prevalence of Chlamydophila pneumoniae is higher in aorta and coronary artery than in carotid artery of coronary artery disease patients," APMIS, vol. 117, no. 12, pp. 905-911, 2009.
16. B. Atik, S. C. Johnston, and D. Dean, "Association of Carotid Plaque Lp-PLA2 with Macrophages and Chlamydia pneumoniae infection among patients at risk for stroke," PLoS ONE, vol. 5, no. 6, Article ID e11026, 2010.
17. A. Luque, M. M. Turu, N. Rovira, J. O. Juan-Babot, M. Slevin, and J. Krupinski, "Early atherosclerotic plaques show evidence of infection by Chlamydia pneumoniae," Frontiers in Bioscience, vol. 4, no. 7, pp. 2423-2432, 2012.
18. J. B. Muhlestein, "Chlamydia pneumoniae-induced atherosclerosis in a rabbit model," Journal of Infectious Diseases, vol. 181, supplement 3, pp. S505-S507, 2000.
19. E. Blessing, L. A. Campbell, M. E. Rosenfeld, N. Chough, and C.-C. Kuo, "Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice," Atherosclerosis, vol. 158, no. 1, pp. 13-17, 2001.
20. S. Chen,K. Shimada,W. Zhang, G. Huang, T. R. Crother, and M. Arditi, "IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice," Journal of Immunology, vol. 185, no. 9, pp. 5619-5627, 2010.
21. F.-Y. Lin, Y.-W. Lin, C.-Y. Huang et al. , "GroEL1, a heat shock protein 60 of Chlamydia pneumoniae, induces lectinlike oxidized low-density lipoprotein receptor 1 expression in endothelial cells and enhances atherogenesis in hypercholesterolemic rabbits," The Journal of Immunology, vol. 186, no. 7, pp. 4405-4414, 2011.
22. C.-Y. Huang, C.-M. Shih, N.-W. Tsao et al. , "GroEL1, from Chlamydia pneumoniae, induces vascular adhesion molecule 1 expression by p37AUF1 in endothelial cells and hypercholesterolemic rabbit," PLoS ONE, vol. 7, no. 8, Article ID e42808, 2012.
23. R. Sorrentino, A. Yilmaz, K. Schubert et al. , "A single infection with Chlamydia pneumoniae is sufficient to exacerbate atherosclerosis in ApoE deficient mice," Cellular Immunology, vol. 294, no. 1, pp. 25-32, 2015.
24. S. S. Wang, M. L. C. Tondella, A. Bajpai et al. , "Circulating Chlamydia pneumoniae DNA and advanced coronary artery disease," International Journal of Cardiology, vol. 118, no. 2, pp. 215-219, 2007.
25. M. Edvinsson, E. Hjelm, S. Thelin, G. Friman, and C. Nyström-Rosander, "Presence of Chlamydophila pneumoniae DNA but not mRNA in stenotic aortic heart valves," International Journal of Cardiology, vol. 143, no. 1, pp. 57-62, 2010.
26. L. Mannonen, E. Markkula, and M. Puolakkainen, "Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts," Medical Microbiology and Immunology, vol. 200, no. 3, pp. 143-154, 2011.
27. M. DiPietro, G. Schiavoni, V. Sessa, F. Pallotta,G. Costanzo, and R. Sessa, "Chlamydia pneumoniae and osteoporosis-associated bone loss: a new risk factor?" Osteoporosis International, vol. 24, no. 5, pp. 1677-1682, 2013.
28. M. Di Pietro, S. Filardo, S. Cazzavillan et al. , "Could past Chlamydial vascular infection promote the dissemination of Chlamydia pneumoniae to the brain?" Journal of Biological Regulator and Homeostatic Agents, vol. 27, no. 1, pp. 155-164, 2013.
29. H. Klvegren, J. Andersson, M. Grenegård, and T. Bengtsson, "Platelet activation triggered by Chlamydia pneumoniae is antagonized by 12-lipoxygenase inhibitors but not cyclooxygenase inhibitors," European Journal of Pharmacology, vol. 566, no. 1-3, pp. 20-27, 2007.
30. J. M. Kern, V. Maass, and M. Maass, "Chlamydia pneumoniae adversely modulates vascular cell properties by direct interaction with signalling cascades,"Thrombosis and Haemostasis, vol. 102, no. 6, pp. 1064-1070, 2009.
31. M. N. Chahine, J. Deniset, E. Dibrov et al. , "Oxidized LDL promotes the mitogenic actions of Chlamydia pneumoniae in vascular smoothmuscle cells," Cardiovascular Research, vol. 92, no. 3, pp. 476-483, 2011.
32. L. A. Campbell, A. W. Lee, M. E. Rosenfeld, and C.-C. Kuo, "Chlamydia pneumoniae induces expression of pro-atherogenic factors through activation of the lectin-like oxidized LDL receptor-1," Pathogens and Disease, vol. 69, no. 1, pp. 1-6, 2013.
33. G.-J. Zhao, Z.-C. Mo, S.-L. Tang et al. , "Chlamydia pneumoniae negatively regulates ABCA1 expression via TLR2-Nuclearfactor-kappa B and miR-33 pathways in THP-1 macrophagederived foam cells," Atherosclerosis, vol. 235, no. 2, pp. 519-525, 2015.
34. C. A. Gaydos, "Growth in vascular cells and cytokine production by Chlamydia pneumoniae," Journal of Infectious Diseases, vol. 181, no. 6, pp. S473-S478, 2000.
35. F. Cao, A. Castrillo, P. Tontonoz, F. Re, and G. I. Byrne, "Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by toll-like receptor 2," Infection and Immunity, vol. 75, no. 2, pp. 753-759, 2007.
36. M. Högdahl, G. Söderlund, and E. Kihlström, "Expression of chemokines and adhesion molecules in human coronary artery endothelial cells infected with Chlamydia (Chlamydophila) pneumoniae," APMIS, vol. 116, no. 12, pp. 1082-1088, 2008.
37. W. Liu, P. He, B. Cheng, C.-L. Mei, Y.-F. Wang, and J.-J. Wan, "Chlamydia pneumoniae disturbs cholesterol homeostasis in human THP-1 macrophages via JNK-PPARγ dependent signal transduction pathways," Microbes and Infection, vol. 12, no. 14-15, pp. 1226-1235, 2010.
38. M. Di Pietro, F. de Santis, G. Schiavoni, S. Filardo, and R. Sessa, "Resveratrol in Chlamydia pneumoniae-induced foam cell formation and interleukin-17A synthesis," Journal of Biological Regulators and Homeostatic Agents, vol. 27, no. 2, pp. 509-518, 2013.
39. B. Wang, L. Zhang, T. Zhang et al. , "Chlamydia pneumoniae infection promotes vascular smooth muscle cell migration through a toll-like receptor 2-related signaling pathway," Infection and Immunity, vol. 81, no. 12, pp. 4583-4591, 2013.
40. M. Di Pietro, S. Filardo, F. De Santis, P. Mastromarino, and R. Sessa, "Chlamydia pneumoniae and oxidative stress in cardiovascular disease: state of the art and prevention strategies," International Journal of Molecular Sciences, vol. 16, no. 1, pp. 724-735, 2015.
41. R. V. Schoborg, "Chlamydia persistence-a tool to dissect Chlamydia-host interactions," Microbes and Infection, vol. 13, no. 7, pp. 649-662, 2011.
42. M. DiPietro, S. Filardo, F. De Santis, and R. Sessa, "New insights into Chlamydiae persistence: an energy metabolism strategy?" International Journal of Immunopathology and Pharmacology, vol. 26, no. 2, pp. 525-528, 2013.
43. L. A. Campbell, K. Yaraei, B. Van Lenten et al. , "The acute phase reactant response to respiratory infectionwith Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis," Microbes and Infection, vol. 12, no. 8-9, pp. 598-606, 2010.
44. J. L. anderson, J. F. Carlquist, J. B. Muhlestein, B. D. Horne, and S. P. Elmer, "Evaluation of c-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction," Journal of the American College of Cardiology, vol. 32, no. 1, pp. 35-41, 1998.
45. H. Toss, J. Gnarpe, H. Gnarpe, A. Siegbahn, B. Lindahl, and L. Wallentin, "Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease," European Heart Journal, vol. 19, no. 4, pp. 570-577, 1998.
46. M. Gattone, L. Iacoviello, M. Colombo et al. , "Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age," American Heart Journal, vol. 142, no. 4, pp. 633-640, 2001.
47. D. Sander, K. Winbeck, J. Klingelhöfer, T. Etgen, and B. Conrad, "Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity," Circulation, vol. 103, no. 10, pp. 1390-1395, 2001.
48. R. Altman, J. Rouvier, A. Scazziota, and C. Gonzalez, "No causal association between inflammation and Chlamydia pneumoniae in patients with chronic ischemic arterial disease," Inflammation, vol. 26, no. 1, pp. 25-30, 2002.
49. D. G. M. Bloemenkamp, W. P. T. M. Mali, B. C. Tanis et al. , "Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women," Atherosclerosis, vol. 163, no. 1, pp. 149-156, 2002.
50. A. Schumacher, I. Seljeflot, A. B. Lerkerod, L. Sommervoll, J. E. Otterstad, and H. Arnesen, "Positive Chlamydia pneumoniae serology is associated with elevated levels of tumor necrosis factor alpha in patients with coronary heart disease," Atherosclerosis, vol. 164, no. 1, pp. 153-160, 2002.
51. L. M. Biasucci, G. Liuzzo, A. Ciervo et al. , "Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes," Circulation, vol. 107, no. 24, pp. 3015-3017, 2003.
52. A. S. Gabriel, S. Ahnve, H. Gnarpe, J. Gnarpe, and A. Martinsson, "Azithromycin therapy in patients with chronic Chlamydia pneumoniae infection and coronary heart disease: immediate and long-term effects on inflammation, coagulation, and lipid status in a double-blind, placebo-controlled study," European Journal of Internal Medicine, vol. 14, no. 8, pp. 470-478, 2003.
53. J.-L. Georges, H. J. Rupprecht, S. Blankenberg et al. , "Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines," The American Journal of Cardiology, vol. 92, no. 5, pp. 515-521, 2003.
54. M. N. Zairis, O. A. Papadaki, P. K. Psarogianni et al. , "Serologic markers of persistent Chlamydia pneumonia infection and longterm prognosis after successful coronary stenting," American Heart Journal, vol. 146, no. 6, pp. 1082-1089, 2003.
55. G. A. Lanza, A. Sestito, G. Cammarota et al. , "Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X," American Journal of Cardiology, vol. 94, no. 1, pp. 40-44, 2004.
56. J. P. Linares-Palomino, J. Gutiérrez, C. Lopez-Espada, J. D. D. Luna, E. Ros, and C. Maroto, "Genomic, serologic, and clinical case-control study of Chlamydia pneumoniae and peripheral artery occlusive disease," Journal of Vascular Surgery, vol. 40,no. 2, pp. 359-366, 2004.
57. A. K. Adiloglu, R. Can, C. Nazli et al. , "Ectasia and severe atherosclerosis: relationships with Chlamydia pneumoniae, Helicobacter pylori, and inflammatory markers," Texas Heart Institute Journal, vol. 32, no. 1, pp. 21-27, 2005.
58. A. Schumacher, I. Seljeflot, A. B. Lerkerod, L. Sommervoll, J. E. Otterstad, and H. Arnesen, "Chlamydia LPS and MOMP seropositivity are associated with different cytokine profiles in patients with coronary heart disease," European Journal of Clinical Investigation, vol. 35, no. 7, pp. 431-437, 2005.
59. E. Corrado, M. Rizzo, R. Tantillo et al. , "Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study," Stroke, vol. 37, no. 2, pp. 482-486, 2006.
60. K. Jitsuiki, K. Yamane, M. Nakajima et al. , "Association of Chlamydia pneumoniae infection and carotid intima-media wall thickness in Japanese Americans," Circulation Journal, vol. 70, no. 7, pp. 815-819, 2006.
61. E. A. Kaperonis, C. D. Liapis, J. D. Kakisis et al. , "Inflammation and Chlamydia pneumoniae infection correlatewith the severityof peripheral arterial disease," European Journal of Vascular and Endovascular Surgery, vol. 31, no. 5, pp. 509-515, 2006.
62. C. Romano Carratelli, I. Nuzzo, D. Cozzolino, C. Bentivoglio, R. Paolillo, and A. Rizzo, "Relationship between Chlamydia pneumoniae infection, inflammatory markers, and coronary heart diseases," International Immunopharmacology, vol. 6, no. 5, pp. 848-853, 2006.
63. V. Videm, R. Wiseth, S. Gunnes, H. O. Madsen, and P. Garred, "Multiple inflammatory markers in patients with significant coronary artery disease," International Journal of Cardiology, vol. 118, no. 1, pp. 81-87, 2007.
64. A. Jafarzadeh, A. Esmaeeli-Nadimi, and M. Shariati, "High sensitivity C-reactive protein and immunoglobulin G against Chlamydia Pneumoniae and Chlamydial heat shock protein-60 in ischemic heart disease," Iranian Journal of Immunology, vol. 5, no. 1, pp. 51-56, 2008.
65. H. C. Jha, P. Srivastava, R. Sarkar, J. Prasad, and A. S. Mittal, "Association of plasma circulatory markers, Chlamydia pneumoniae, and high sensitive C-reactive protein in coronary artery disease patients of India," Mediators of Inflammation, vol. 2009, Article ID 561532, 5 pages, 2009.
66. A. Nazmi, A. V. Diez-Roux, N. S. Jenny, M. Y. Tsai, M. Szklo, and A. E. Aiello, "The influence of persistent pathogens on circulating levels of inflammatory markers: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis," BMC Public Health, vol. 10, article 706, 2010.
67. M. Haider, M. Rizvi, A. Malik, M. Azam, and M. U. Rabbani, "Acute and chronic Chlamydia pneumoniae infection and inflammatory markers in coronary artery disease patients," Journal of Infection in Developing Countries, vol. 5, no. 8, pp. 580-586, 2011.
68. L. A. Mundkur,V. S. Rao, S. Hebbagudi et al. , "Pathogen burden, cytomegalovirus infection and inflammatory markers in the risk of premature coronary artery disease in individuals of Indian origin," Experimental and Clinical Cardiology, vol. 17, no. 2, pp. 63-68, 2012.
69. A. K. Pandey, S. Pandey, M. J. Blaha et al. , "Family history of coronary heart disease and markers of subclinical cardiovascular disease: where do we stand?" Atherosclerosis, vol. 228, no. 2, pp. 285-294, 2013.